Magdalini Tsolaki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3388110/publications.pdf

Version: 2024-02-01

458 papers

37,593 citations

4960 84 h-index 172 g-index

490 all docs

490 docs citations

490 times ranked

37942 citing authors

#	Article	IF	CITATIONS
1	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.8	4
2	Rey Complex Figure Test (RCFT): Norms for the Greek older adult population. Applied Neuropsychology Adult, 2022, 29, 958-966.	1.2	12
3	Frontotemporal dementia and financial capacity: facing the Cerberus of overestimation or underestimation?. Australasian Psychiatry, 2022, 30, 41-43.	0.7	11
4	Age-related Differences in Mu Rhythm During Emotional Destination Memory Task. Current Aging Science, 2022, 15, 26-36.	1.2	3
5	Comparison of on Site versus Online Psycho Education Groups and Reducing Caregiver Burden. Clinical Gerontologist, 2022, 45, 1330-1340.	2.2	13
6	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
7	Longitudinal Study of Depression on Amnestic Mild Cognitive Impairment and Financial Capacity. Clinical Gerontologist, 2022, 45, 708-714.	2.2	13
8	Financial Incapacity of Patients with Mild Alzheimer's Disease: What Neurologists Need to Know about Where the Impairment Lies. Neurology International, 2022, 14, 90-98.	2.8	10
9	Non-Pharmacological Interventions for Wandering/Aberrant Motor Behaviour in Patients with Dementia. Brain Sciences, 2022, 12, 130.	2.3	3
10	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. Alzheimer's and Dementia, 2022, 18, 1957-1968.	0.8	2
11	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. Molecular Psychiatry, 2022, 27, 1990-1999.	7.9	9
12	The discriminant validity of Rey Complex Figure Test (RCFT) in subjective cognitive decline, mild cognitive impairment (multiple domain) and Alzheimer's disease dementia (ADD; mild stage) in Greek older adults. Applied Neuropsychology Adult, 2022, , 1-10.	1.2	5
13	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. Molecular Neurodegeneration, 2022, 17, 27.	10.8	30
14	Emotional Function, Negative Thoughts about the Pandemic, and Adaptability Skills among Dementia Caregivers during the COVID-19 Pandemic. Brain Sciences, 2022, 12, 459.	2.3	2
15	Exploring Network Properties Across Preclinical Stages of Alzheimer's Disease Using a Visual Short-Term Memory and Attention Task with High-Density Electroencephalography: A Brain-Connectome Neurophysiological Study. Journal of Alzheimer's Disease, 2022, 87, 643-664.	2.6	4
16	Liberating older adults from the bonds of vascular risk factors: What is their impact on financial capacity in amnestic mild cognitive impairment?. Psychiatry and Clinical Neurosciences, 2022, , .	1.8	6
17	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
18	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26

#	Article	IF	CITATIONS
19	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.8	22
20	Effects of age, amyloid, sex, and <i>APOE</i> $\hat{l}\mu 4$ on the CSF proteome in normal cognition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, e12286.	2.4	4
21	Usability of the Virtual Supermarket Test for Older Adults with and without Cognitive Impairment. Journal of Alzheimer's Disease Reports, 2022, 6, 229-234.	2.2	6
22	Assess of Combinations of Non-Pharmacological Interventions for the Reduction of Irritability in Patients with Dementia and their Caregivers: A Cross-Over RCT. Brain Sciences, 2022, 12, 691.	2.3	0
23	Natural products against neurodegenerative disease progression. , 2022, 2, .		0
24	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
25	Informal Caregivers' Attitude Toward Dementia: The Impact of Dementia Knowledge, Confidence in Dementia Care, and the Behavioral and Psychological Symptoms of the Person with Dementia. A Cross-Sectional Study. Journal of Alzheimer's Disease, 2022, 88, 971-984.	2.6	9
26	The development of a blended learning course and Back-end as a Service System for educating university students on Genetic Counseling, 2022,,.		0
27	An e-learning platform for training on teaching English to people with mild cognitive impairment (M.C.I.) with the use of songs. , 2022, , .		0
28	Innovative Serious Games for People with Dementia developed through intergenerational interventions, 2022, , .		4
29	Is negative affect associated with deficits in financial capacity in nondepressed older adults? A preliminary study. Journal of Affective Disorders Reports, 2022, 10, 100391.	1.7	5
30	Restoration of BMI1 levels after the administration of early harvest extra virgin olive oil as a therapeutic strategy against Alzheimer's disease. Experimental Gerontology, 2021, 144, 111178.	2.8	19
31	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. Magnetic Resonance Imaging, 2021, 76, 108-115.	1.8	24
32	Mild Alzheimer Disease, Financial Capacity, and the Role of Depression. Alzheimer Disease and Associated Disorders, 2021, Publish Ahead of Print, 360-362.	1,3	15
33	Setting Up a Cognitive Training Service for Egyptian Older Adults. Journal of Alzheimer's Disease, 2021, 79, 1673-1682.	2.6	2
34	A Comparison of Traditional and Serious Game-Based Digital Markers of Cognition in Older Adults with Mild Cognitive Impairment and Healthy Controls. Journal of Alzheimer's Disease, 2021, 79, 1747-1759.	2.6	23
35	Î' Virtual Reality App for Physical and Cognitive Training of Older People With Mild Cognitive Impairment: Mixed Methods Feasibility Study. JMIR Serious Games, 2021, 9, e24170.	3.1	35
36	A Virtual Reality-Based Screening Test for Cognitive Impairment in Small Vessel Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 161-169.	2.2	3

#	Article	IF	CITATIONS
37	The Contribution of Ocular Biomarkers in the Differential Diagnosis of Alzheimer's Disease versus Other Types of Dementia and Future Prospects. Journal of Alzheimer's Disease, 2021, 80, 493-504.	2.6	9
38	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	8.8	49
39	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.8	13
40	Wearable Devices for Assessing Function in Alzheimer's Disease: A European Public Involvement Activity About the Features and Preferences of Patients and Caregivers. Frontiers in Aging Neuroscience, 2021, 13, 643135.	3.4	22
41	Rationale, Design, and Methodology of a Prospective Cohort Study for Coping with Behavioral and Psychological Symptoms of Dementia: The RECage Project1. Journal of Alzheimer's Disease, 2021, 80, 1613-1627.	2.6	8
42	Similar Theory of Mind Deficits in Community Dwelling Older Adults with Vascular Risk Profile and Patients with Mild Cognitive Impairment: The Case of Paradoxical Sarcasm Comprehension. Brain Sciences, 2021, 11 , 627 .	2.3	7
43	Ocular biomarkers and their role in the early diagnosis of neurocognitive disorders. European Journal of Ophthalmology, 2021, 31, 112067212110163.	1.3	10
44	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
45	Human Factors and Requirements of People with Cognitive Impairment, Their Caregivers, and Healthcare Professionals for mHealth Apps Including Reminders, Games, and Geolocation Tracking: A Survey-Questionnaire Study. Journal of Alzheimer's Disease Reports, 2021, 5, 497-513.	2.2	3
46	Longitudinal Cognitive and Physical Training Effectiveness in MCI, Based on the Experience of the Alzheimer's Hellas Day Care Centre. Journal of Geriatric Psychiatry and Neurology, 2021, , 089198872110160.	2.3	8
47	Is Depression or Apathy Playing a Key Role in Predicting Financial Capacity in Parkinson's Disease with Dementia and Frontotemporal Dementia?. Brain Sciences, 2021, 11, 785.	2.3	11
48	Discriminant Validity of the WAIS-R Digit Symbol Substitution Test in Subjective Cognitive Decline, Mild Cognitive Impairment (Amnestic Subtype) and Alzheimer's Disease Dementia (ADD) in Greece. Brain Sciences, 2021, 11, 881.	2.3	12
49	The pleiotropic beneficial intervention of olive oil intake on the Alzheimer's disease onset via fibrinolytic system. Experimental Gerontology, 2021, 150, 111344.	2.8	9
50	Measuring Impulsivity in Greek Adults: Psychometric Properties of the Barratt Impulsiveness Scale (BIS-11) and Impulsive Behavior Scale (Short Version of UPPS-P). Brain Sciences, 2021, 11, 1007.	2.3	6
51	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	3 . 5	9
52	Greek High Phenolic Early Harvest Extra Virgin Olive Oil Reduces the Over-Excitation of Information-Flow Based on Dominant Coupling Mode (DoCM) Model in Patients with Mild Cognitive Impairment: An EEG Resting-State Validation Approach. Journal of Alzheimer's Disease, 2021, 83, 191-207.	2.6	8
53	Are There Any Cognitive and Behavioral Changes Potentially Related to Quarantine Due to the COVID-19 Pandemic in People with Mild Cognitive Impairment and AD Dementia? A Longitudinal Study. Brain Sciences, 2021, 11, 1165.	2.3	10
54	Involvement and relationship of bacterial lipopolysaccharides and cyclooxygenases levels in Alzheimer's Disease and Mild Cognitive Impairment patients. Journal of Neuroimmunology, 2021, 357, 577561.	2.3	7

#	Article	IF	CITATIONS
55	Memory Clinics and Day Care Centers in Thessaloniki, Northern Greece: 30 Years of Clinical Practice and Experience. Frontiers in Neurology, 2021, 12, 683131.	2.4	1
56	Detection of Health-Related Events and Behaviours from Wearable Sensor Lifestyle Data Using Symbolic Intelligence: A Proof-of-Concept Application in the Care of Multiple Sclerosis. Sensors, 2021, 21, 6230.	3.8	8
57	Financial Capacity and Illiteracy: Does Education Matter in Amnestic Mild Cognitive Impairment?. Journal of Alzheimer's Disease Reports, 2021, 5, 715-719.	2.2	9
58	APOE É>4 Allele and Financial Capacity Performance in Mild Alzheimer's Disease: A Pilot Study. Journal of Alzheimer's Disease Reports, 2021, 5, 93-97.	2.2	11
59	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.8	174
60	Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimerâ \in [™] s disease. Alzheimer's Research and Therapy, 2021, 13, 20.	6.2	60
61	Extracellular GAPDH Promotes Alzheimer Disease Progression by Enhancing Amyloid- \hat{l}^2 Aggregation and Cytotoxicity. , 2021, 12, 1223.		16
62	Vascular Dementia, Depression, and Financial Capacity Assessment. Alzheimer Disease and Associated Disorders, 2021, 35, 84-87.	1.3	23
63	Adaptation and Validation of the Memory Alteration Test (M@T) in Greek Middle-Aged, Older, and Older-Old Population with Subjective Cognitive Decline and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 84, $1-14$.	2.6	2
64	Salivary GFAP as a potential biomarker for diagnosis of mild cognitive impairment and Alzheimer's disease and its correlation with neuroinflammation and apoptosis. Journal of Neuroimmunology, 2021, 361, 577744.	2.3	20
65	Extra Virgin Olive Oil consumption from Mild Cognitive Impairment patients attenuates oxidative and nitrative stress reflecting on the reduction of the PARP levels and DNA damage. Experimental Gerontology, 2021, 156, 111621.	2.8	9
66	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
67	Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD. Journal of the American Medical Directors Association, 2020, 21, 194-200.	2.5	21
68	A new tool to assess amnestic mild cognitive impairment in Turkish older adults: virtual supermarket (VSM). Aging, Neuropsychology, and Cognition, 2020, 27, 639-653.	1.3	27
69	CSF cutoffs for MCI due to AD depend on APOEε4 carrier status. Neurobiology of Aging, 2020, 89, 55-62.	3.1	11
70	Detection of Mild Cognitive Impairment in an At-Risk Group of Older Adults: Can a Novel Self-Administered Serious Game-Based Screening Test Improve Diagnostic Accuracy?. Journal of Alzheimer's Disease, 2020, 78, 405-412.	2.6	19
71	Detection of Mild Cognitive Impairment Through Natural Language and Touchscreen Typing Processing. Frontiers in Digital Health, 2020, 2, 567158.	2.8	22
72	A Randomized Clinical Trial of Greek High Phenolic Early Harvest Extra Virgin Olive Oil in Mild Cognitive Impairment: The MICOIL Pilot Study. Journal of Alzheimer's Disease, 2020, 78, 801-817.	2.6	43

#	Article	IF	CITATIONS
73	Human Factors and Requirements of People with Mild Cognitive Impairment, their Caregivers and Healthcare Professionals for eHealth Systems with Wearable Trackers. , 2020, , .		1
74	Is the Discrimination of Subjective Cognitive Decline from Cognitively Healthy Adulthood and Mild Cognitive Impairment Possible? A Pilot Study Utilizing the R4Alz Battery. Journal of Alzheimer's Disease, 2020, 77, 715-732.	2.6	8
75	The genetic architecture of human brainstem structures and their involvement in common brain disorders. Nature Communications, 2020, 11, 4016.	12.8	26
76	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiology of Aging, 2020, 95, 26-45.	3.1	51
77	A French–Greek Cross-Site Comparison Study of the Use of Automatic Video Analyses for the Assessment of Autonomy in Dementia Patients. Biosensors, 2020, 10, 103.	4.7	7
78	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	2.6	7
79	Digital biomarkerâ€based individualized prognosis for people at risk of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12073.	2.4	28
80	Sedative Load in Community-Dwelling Older Adults with Mild–Moderate Alzheimer's Disease: Longitudinal Relationships with Adverse Events, Delirium and Falls. Drugs and Aging, 2020, 37, 829-837.	2.7	5
81	Assessing the Attitudes of Greek Nurses Toward Computerized Dementia Screening. Journal of Alzheimer's Disease, 2020, 78, 1575-1583.	2.6	4
82	Effects of a Person Centered Dementia Training Program in Greek Hospital Staffâ€"Implementation and Evaluation. Brain Sciences, 2020, 10, 976.	2.3	10
83	Urinary metabolic phenotyping for Alzheimer's disease. Scientific Reports, 2020, 10, 21745.	3.3	30
84	Evaluation and Effectiveness of Dementia Staff Training Programs in General Hospital Settings: A Narrative Synthesis with Holton's Three-Level Model Applied. Journal of Alzheimer's Disease, 2020, 78, 1089-1108.	2.6	15
85	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. Medical Image Analysis, 2020, 66, 101714.	11.6	90
86	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	2.6	13
87	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. NeuroImage, 2020, 218, 116932.	4.2	38
88	Non-Pharmacological interventions for the anxiety in patients with dementia. A cross-over randomised controlled trial. Behavioural Brain Research, 2020, 390, 112617.	2.2	14
89	APOE ε4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 65.	6.2	28
90	The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD Trial. Frontiers in Neurology, 2020, 11, 149.	2.4	14

#	Article	IF	CITATIONS
91	Modeling and Targeting Alzheimer's Disease With Organoids. Frontiers in Pharmacology, 2020, 11, 396.	3.5	71
92	A probable role of copper in the comorbidity in Wilson's and Creutzfeldt-Jakob's Diseases: a case report. Virology Journal, 2020, 17, 35.	3.4	3
93	A Novel Connectome-based Electrophysiological Study of Subjective Cognitive Decline Related to Alzheimer's Disease by Using Resting-state High-density EEG EGI GES 300. Brain Sciences, 2020, 10, 392.	2.3	17
94	West Nile neuroinvasive disease. Report of four cases in Northern Greece, 2018. Journal of Medical Virology, 2020, 92, 1322-1325.	5.0	1
95	Editorial: Cognitive Impairment: Therapy Momentum in the Continuum of Life. Frontiers in Pharmacology, 2020, 11, 618344.	3.5	0
96	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	7.6	89
97	Unraveling Ariadne's Thread Into the Labyrinth of aMCI. Alzheimer Disease and Associated Disorders, 2020, Publish Ahead of Print, 363-365.	1.3	20
98	Depression in Dementia or Dementia in Depression? Systematic Review of Studies and Hypotheses. Current Alzheimer Research, 2020, 17, 16-28.	1.4	33
99	Web-Based Intervention Effects on Mild Cognitive Impairment Based on Apolipoprotein E Genotype: Quasi-Experimental Study. Journal of Medical Internet Research, 2020, 22, e14617.	4.3	4
100	Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers. Journal of Alzheimer's Disease, 2019, 69, 3-14.	2.6	18
101	Validation of the Rowland Universal Dementia Assessment Scale (RUDAS) in a multicultural sample across five Western European countries: diagnostic accuracy and normative data. International Psychogeriatrics, 2019, 31, 287-296.	1.0	18
102	Is brain connectome research the future frontier for subjective cognitive decline? A systematic review. Clinical Neurophysiology, 2019, 130, 1762-1780.	1.5	25
103	Long-Term Impact of Intelligent Monitoring Technology on People with Cognitive Impairment: An Observational Study. Journal of Alzheimer's Disease, 2019, 70, 757-792.	2.6	23
104	Expectations of nursing personnel and physicians onÂdementia training. Zeitschrift Fur Gerontologie Und Geriatrie, 2019, 52, 249-257.	1.8	5
105	Views of nursing staff on computerized dementia screening. Zeitschrift Fur Gerontologie Und Geriatrie, 2019, 52, 258-263.	1.8	2
106	REMEDES for Alzheimer-R4Alz Battery: Design and Development of a New Tool of Cognitive Control Assessment for the Diagnosis of Minor and Major Neurocognitive Disorders. Journal of Alzheimer's Disease, 2019, 72, 783-801.	2.6	4
107	Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1875-1881.	2.3	20
108	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.8	46

#	Article	IF	CITATIONS
109	The Pattern of Mu Rhythm Modulation During Emotional Destination Memory: Comparison Between Mild Cognitive Impairment Patients and Healthy Controls. Journal of Alzheimer's Disease, 2019, 71, 1201-1215.	2.6	5
110	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	10.2	85
111	Cognition in Vascular Aging and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 72, 55-70.	2.6	8
112	Common brain disorders are associated with heritable patterns of apparent aging of the brain. Nature Neuroscience, 2019, 22, 1617-1623.	14.8	358
113	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. Alzheimer's and Dementia, 2019, 15, 888-898.	0.8	290
114	Normative Data for the Montreal Cognitive Assessment in Greek Older Adults With Subjective Cognitive Decline, Mild Cognitive Impairment and Dementia. Journal of Geriatric Psychiatry and Neurology, 2019, 32, 265-274.	2.3	36
115	Blood Pressure Lowering With Nilvadipine in Patients With Mildâ€toâ€Moderate Alzheimer Disease Does Not Increase the Prevalence of Orthostatic Hypotension. Journal of the American Heart Association, 2019, 8, e011938.	3.7	10
116	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.8	62
117	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.8	134
118	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 281-289.	1.9	10
119	Extensive validation study of the Parkinson's Disease Composite Scale. European Journal of Neurology, 2019, 26, 1281-1288.	3.3	8
120	Validation of a brief Multicultural Cognitive Examination (MCE) for evaluation of dementia. International Journal of Geriatric Psychiatry, 2019, 34, 982-989.	2.7	12
121	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.8	90
122	Impact of <i>Helicobacter pylori</i> and/or <i>Helicobacter pylori</i> –related metabolic syndrome on incidence of all ause and Alzheimer‧s dementia. Alzheimer's and Dementia, 2019, 15, 723-725.	0.8	16
123	Greek Traditional Dances: A Way to Support Intellectual, Psychological, and Motor Functions in Senior Citizens at Risk of Neurodegeneration. Frontiers in Aging Neuroscience, 2019, 11, 6.	3.4	29
124	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.8	82
125	A Comparative Single-Blind Randomized Controlled Trial With Language Training in People With Mild Cognitive Impairment. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 176-187.	1.9	18
126	Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 69, 49-58.	2.6	8

#	Article	IF	CITATIONS
127	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
128	Greek Adaptation of the Positive Aspects of Caregiving (PAC) Scale in Dementia Caregivers. Clinical Gerontologist, 2019, , 1-10.	2.2	4
129	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	3.7	70
130	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	21.4	192
131	Plasma Aβ42 as a Biomarker of Prodromal Alzheimer's Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI Study. Journal of Alzheimer's Disease, 2019, 69, 37-48.	2.6	23
132	Two-Year Longitudinal Monitoring of Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease Using Topographical Biomarkers Derived from Functional Magnetic Resonance Imaging and Electroencephalographic Activity. Journal of Alzheimer's Disease, 2019, 69, 15-35.	2.6	34
133	The repeatable battery for the assessment of the neuropsychological status (RBANS): a diagnostic validity study in Greek elderly. Aging Clinical and Experimental Research, 2019, 31, 1305-1312.	2.9	6
134	The Role of Gender in Shame, Hostility, and Aggression Experienced by Caregivers for Patients With Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2019, 34, 231-235.	1.9	2
135	Validation of a European Cross ultural Neuropsychological Test Battery (CNTB) for evaluation of dementia. International Journal of Geriatric Psychiatry, 2019, 34, 144-152.	2.7	24
136	Putative autoantibodies in the cerebrospinal fluid of Alzheimer's disease patients. F1000Research, 2019, 8, 1900.	1.6	13
137	Future strategies of management of Alzheimer's Disease. The role of homotaurine. Hellenic Journal of Nuclear Medicine, 2019, 22 Suppl, 82-94.	0.3	6
138	Are left angular gyrus and amygdala volumes important for financial capacity in mild cognitive impairment?. Hellenic Journal of Nuclear Medicine, 2019, 22 Suppl, 160-164.	0.3	4
139	Heterogeneous patterns of brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2018, 65, 98-108.	3.1	110
140	Performance of middle-aged and elderly European minority and majority populations on a Cross-Cultural Neuropsychological Test Battery (CNTB). Clinical Neuropsychologist, 2018, 32, 1411-1430.	2.3	40
141	Random forest feature selection, fusion and ensemble strategy: Combining multiple morphological MRI measures to discriminate among healhy elderly, MCI, cMCI and alzheimer's disease patients: From the alzheimer's disease neuroimaging initiative (ADNI) database. Journal of Neuroscience Methods, 2018, 302, 14-23.	2.5	105
142	Prevalence of the apolipoprotein E $\hat{l}\mu4$ allele in amyloid \hat{l}^2 positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
143	A computerized test for the assessment of mild cognitive impairment subtypes in sentence processing. Aging, Neuropsychology, and Cognition, 2018, 25, 829-851.	1.3	4
144	Association of Cerebral Amyloid- \hat{l}^2 Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133

#	Article	IF	CITATIONS
145	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. Neurobiology of Aging, 2018, 62, 245.e1-245.e7.	3.1	16
146	P3â€368: PREDICTING AND MONITORING SHORTâ€TERM DISEASE PROGRESSION IN Aâ€MCI PATIENTS WITH PRODROMAL AD USING MRI STRUCTURAL BRAIN BIOMARKERS. Alzheimer's and Dementia, 2018, 14, P1230.	0.8	0
147	P2â€270: INCREASED CSF AMYLOIDâ€Î² 1â€38 AND 1â€40 CONCENTRATIONS IN INDIVIDUALS WITH MILD COGI IMPAIRMENT WITH TAU BUT WITHOUT AMYLOID PATHOPHYSIOLOGY. Alzheimer's and Dementia, 2018, 14, P780.	NITIVE 0.8	О
148	O1â€13â€01: ROLE OF THE INFLAMMASOME COMPLEX IN ADâ€RELATED HIPPOCAMPAL NEURODEGENERATION PATIENTS WITH AD PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P251.	IN MCI 0.8	0
149	P2â€101: Aβ/PHOSPHO TAU LOAD IN CSF IS RELATED TO CORTICAL EXCITABILITY AS REVEALED BY CORTICAL EE BIOMARKERS IN PATIENTS WITH PRODROMAL ALZHEIMER'S DISEASE: THE PHARMACOG PROJECT. Alzheimer's and Dementia, 2018, 14, P707.	G 0.8	О
150	ICâ€Pâ€126: VOLUMETRIC ACCURACY OF A FULLY AUTOMATIC TOOL FOR WHITE MATTER HYPERINTENSITIES (WMHS) SEGMENTATION. Alzheimer's and Dementia, 2018, 14, P105.	0.8	1
151	F1â€02â€04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P204.	0.8	O
152	P2â€209: HIGH CONCENTRATIONS OF ANTIBODIES RECOGNIZING EGGâ€ALBUMIN AND BOVINE CASEIN IN THE CONCENTRATIONS OF ANTIBODIES RECOGNIZING EGGâ€ALBUMIN AND BOVINE CASEIN IN THE CONCENTRATIONS WITH SEVERE ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P748.	CSF 0.8	0
153	Mining clinical and laboratory data of neurodegenerative diseases by Machine Learning: transcriptomic biomarkers. , 2018, , .		2
154	Enhancement of Visuospatial Working Memory by the Differential Outcomes Procedure in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 364.	3.4	10
155	F1â€02â€01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENTâ€LIGHT AND YKLâ€40 TO Aβ, APOE Îμ4 COGNITION: RESULTS FROM THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P201.	AND 0.8	O
156	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. Alzheimer's Research and Therapy, 2018, 10, 100.	6.2	64
157	Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial. PLoS Medicine, 2018, 15, e1002660.	8.4	131
158	P2â€458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P895.	0.8	O
159	F1â€02â€03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVER STUDY. Alzheimer's and Dementia, 2018, 14, P202.	8.8	0
160	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	2.6	12
161	P4â€077: BLOOD INFLAMMATORY PROFILES MEASURED BY THE ADFLAG [®] TEST ENABLE STRATIFICATION OF PREâ€DEMENTIA ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1464.	0.8	O
162	Prevalence of Apolipoprotein E Polymorphisms in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: A Northern Greece Study. Neurodegenerative Diseases, 2018, 18, 216-224.	1.4	14

#	Article	IF	Citations
163	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
164	Amyloid- \hat{l}^2 , Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data. Frontiers in Aging Neuroscience, 2018, 10, 193.	3.4	16
165	EEG-Based Brain–Computer Interfaces for Communication and Rehabilitation of People with Motor Impairment: A Novel Approach of the 21st Century. Frontiers in Human Neuroscience, 2018, 12, 14.	2.0	213
166	The Impact of a Long-Term Rivastigmine and Donepezil Treatment on All-Cause Mortality in Patients With Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2018, 33, 385-393.	1.9	7
167	Can a Novel High-Density EEG Approach Disentangle the Differences of Visual Event Related Potential (N170), Elicited by Negative Facial Stimuli, in People with Subjective Cognitive Impairment?. Journal of Alzheimer's Disease, 2018, 65, 543-575.	2.6	14
168	Stability of graph theoretical measures in structural brain networks in Alzheimer's disease. Scientific Reports, 2018, 8, 11592.	3.3	41
169	Exploring the Role of Cognitive Factors in a New Instrument for Elders' Financial Capacity Assessment. Journal of Alzheimer's Disease, 2018, 62, 1579-1594.	2.6	37
170	Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 439.	3.4	21
171	Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer's disease progression. F1000Research, 2018, 7, 1012.	1.6	34
172	Cerebral perfusion alterations and cognitive decline in critically ill sepsis survivors. Acta Clinica Belgica, 2017, 72, 39-44.	1.2	16
173	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	12.8	250
174	Mitochondrial genes are altered in blood early in Alzheimer's disease. Neurobiology of Aging, 2017, 53, 36-47.	3.1	132
175	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	2.6	10
176	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's and Dementia, 2017, 13, 903-912.	0.8	32
177	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	1.9	20
178	The impact of automated hippocampal volumetry on diagnostic confidence in patients with suspected Alzheimer's disease: A European Alzheimer's Disease Consortium study. Alzheimer's and Dementia, 2017, 13, 1013-1023.	0.8	33
179	Association between CSF biomarkers, hippocampal volume and cognitive function in patients with amnestic mild cognitive impairment (MCI). Neurobiology of Aging, 2017, 53, 1-10.	3.1	59
180	Prevalence of Dementia, Depression, and Mild Cognitive Impairment in a Rural Area of the Island of Crete, Greece. American Journal of Alzheimer's Disease and Other Dementias, 2017, 32, 252-264.	1.9	19

#	Article	IF	CITATIONS
181	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. Acta Neuropathologica, 2017, 134, 475-487.	7.7	53
182	The Use of the Gaps-In-Noise Test as an Index of the Enhanced Left Temporal Cortical Thinning Associated with the Transition between Mild Cognitive Impairment and Alzheimer's Disease. Journal of the American Academy of Audiology, 2017, 28, 463-471.	0.7	31
183	Brain source localization of MMN and P300 ERPs in mild cognitive impairment and Alzheimer's disease: a high-density EEG approach. Neurobiology of Aging, 2017, 55, 190-201.	3.1	49
184	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	3.1	27
185	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 809-817.	2.6	72
186	A Preliminary Study on the Feasibility ofÂUsing a Virtual Reality Cognitive Training Application for Remote Detection of Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 56, 619-627.	2.6	65
187	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. Journal of Alzheimer's Disease, 2017, 60, 1025-1034.	2.6	33
188	No Genetic Overlap Between Circulating Iron Levels and Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 85-99.	2.6	10
189	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1119-1128.	2.6	27
190	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1387-1395.	2.6	24
191	International Ballroom Dancing Against Neurodegeneration: A Randomized Controlled Trial in Greek Community-Dwelling Elders With Mild Cognitive impairment. American Journal of Alzheimer's Disease and Other Dementias, 2017, 32, 489-499.	1.9	155
192	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
193	Rhamnolipids, Microbial Virulence Factors, in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 59, 209-222.	2.6	25
194	Age-induced differences in brain neural activation elicited by visual emotional stimuli: A high-density EEG study. Neuroscience, 2017, 340, 268-278.	2.3	10
195	Free water elimination improves test–retest reproducibility of diffusion tensor imaging indices in the brain: A longitudinal multisite study of healthy elderly subjects. Human Brain Mapping, 2017, 38, 12-26.	3.6	72
196	Data quality evaluation for observational multiple sclerosis registries. Multiple Sclerosis Journal, 2017, 23, 647-655.	3.0	64
197	Association of blood lipids with Alzheimer's disease: AÂcomprehensiveÂlipidomics analysis. Alzheimer's and Dementia, 2017, 13, 140-151.	0.8	144
198	A monitoring system for people living with Alzheimer's disease. , 2017, , .		8

#	Article	IF	Citations
199	[P4–157]: CSF BIOMARKERS AND EFFECT OF APOLIPOPROTEIN E GENOTYPE, AGE AND SEX ON CUTâ€OFF DERIVATION IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1319.	0.8	4
200	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research and Therapy, 2017, 9, 101.	6.2	43
201	A Multi-Cohort Study of ApoE É>4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 1159-1174.	2.6	36
202	Evaluation of the efficacy of randomized controlled trials of sensory stimulation interventions for sleeping disturbances in patients with dementia: a systematic review. Clinical Interventions in Aging, 2017, Volume 12, 543-548.	2.9	12
203	Technologies to Support Community-Dwelling Persons With Dementia: A Position Paper on Issues Regarding Development, Usability, Effectiveness and Cost-Effectiveness, Deployment, and Ethics. JMIR Rehabilitation and Assistive Technologies, 2017, 4, e1.	2.2	228
204	Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 49, 1105-1114.	2.6	30
205	Clinical and biomarker profiling of prodromal Alzheimer's disease in workpackage 5 of the Innovative Medicines Initiative PharmaCog project: a â€~European <scp>ADNI</scp> study'. Journal of Internal Medicine, 2016, 279, 576-591.	6.0	64
206	Cognitive Impairment in Multiple Sclerosis: A Review of Neuropsychological Assessments. Cognitive and Behavioral Neurology, 2016, 29, 55-67.	0.9	42
207	A Novel and Intelligent Home Monitoring System for Care Support of Elders with Cognitive Impairment. Journal of Alzheimer's Disease, 2016, 54, 1561-1591.	2.6	87
208	Exploring the potential of programming tasks to benefit patients with mild cognitive impairment. , 2016, , .		4
209	Tsallis statistics and neurodegenerative disorders. Journal of the Mechanical Behavior of Materials, 2016, 25, 129-139.	1.8	2
210	The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. Brain Topography, 2016, 29, 296-307.	1.8	44
211	Study of EEG Power Fluctuations Enhanced by Linguistic Stimulus for Cognitive Decline Screening. Communications in Computer and Information Science, 2016, , 165-175.	0.5	1
212	Mnemonic strategy training of the elderly at risk for dementia enhances integration of information processing via crossâ€frequency coupling. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 241-249.	3.7	24
213	Cognitive MMN and P300 in mild cognitive impairment and Alzheimer's disease: A high density EEG-3D vector field tomography approach. Brain Research, 2016, 1648, 425-433.	2.2	43
214	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5. 3	56
215	Efficacy and Safety of Crocus sativus L. inÂPatients with Mild Cognitive Impairment: One Year Single-Blind Randomized, with Parallel Groups, Clinical Trial. Journal of Alzheimer's Disease, 2016, 54, 129-133.	2.6	57
216	Recent Findings in Alzheimer Disease and Nutrition Focusing on Epigenetics. Advances in Nutrition, 2016, 7, 917-927.	6.4	55

#	Article	IF	Citations
217	A New Method for the Assessment of Discourse Comprehension Abilities of Older Adults with Mild Cognitive Impairment. , 2016, , .		1
218	European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's diseaseâ€"the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow. BMJ Open, 2016, 6, e011584.	1.9	21
219	Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. Human Brain Mapping, 2016, 37, 2114-2132.	3.6	38
220	Baseline CSF AÎ ² , AÎ ² /T-TAU and AÎ ² /P-tau distributions to classify pharmacog MCI patients. Neurobiology of Aging, 2016, 39, S30.	3.1	0
221	Disrupted Network Topology in Patients with Stable and Progressive Mild Cognitive Impairment and Alzheimer's Disease. Cerebral Cortex, 2016, 26, 3476-3493.	2.9	110
222	Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. European Radiology, 2016, 26, 2597-2610.	4.5	39
223	Measuring Global Brain Atrophy with the Brain Volume/Cerebrospinal Fluid Index: Normative Values, Cut-Offs and Clinical Associations. Neurodegenerative Diseases, 2016, 16, 77-86.	1.4	29
224	The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. Neurobiology of Aging, 2016, 40, 68-77.	3.1	115
225	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.8	179
226	Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. NeuroImage, 2016, 124, 442-454.	4.2	85
227	<i>Helicobacter pylori</i> related ApoE 4 polymorphism may be associated with dysphagic symptoms in older adults. Ecological Management and Restoration, 2016, 29, 842-842.	0.4	11
228	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
229	Intelligent User Interfaces to Support Diagnosis and Assessment of People with Dementia: An Expert Evaluation. Communications in Computer and Information Science, 2016, , 196-206.	0.5	2
230	MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study. Current Alzheimer Research, 2016, 13, 1407-1413.	1.4	3
231	Rare Variants in <i>PLD3</i> Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. Human Mutation, 2015, 36, 1226-1235.	2.5	23
232	Gender effect in human brain responses to bottom-up and top-down attention using the EEG 3D-Vector Field Tomography., 2015, 2015, 7574-7.		2
233	Generalizability of the Disease State Index Prediction Model for Identifying Patients Progressing from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 79-92.	2.6	31
234	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 741-750.	2.6	2

#	Article	IF	CITATIONS
235	Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels inÂPatients with Alzheimer's Disease?. Journal of Alzheimer's Disease, 2015, 47, 1069-1078.	2.6	28
236	Fiveâ€year biomarker progression variability for Alzheimer's disease dementia prediction: Can a complex instrumental activities of daily living marker fill in the gaps?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 521-532.	2.4	35
237	Practical cutâ€offs for visual rating scales of medial temporal, frontal and posterior atrophy in <scp>A</scp> lzheimer's disease and mild cognitive impairment. Journal of Internal Medicine, 2015, 278, 277-290.	6.0	91
238	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite <scp>E</scp> uropean 3T study on healthy elderly. Human Brain Mapping, 2015, 36, 3516-3527.	3.6	34
239	Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. Current Alzheimer Research, 2015, 12, 69-79.	1.4	22
240	Perception of pain self-efficacy and fatigue in Greek patients with multiple sclerosis: a study protocol. Health Psychology Research, 2015, 3, 1556.	1.4	5
241	A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis. Journal of Alzheimer's Disease, 2015, 49, 659-669.	2.6	43
242	Reliability of a novel serious game using dual-task gait profiles to early characterize aMCI. Frontiers in Aging Neuroscience, 2015, 07, 50.	3.4	32
243	Gains in cognition through combined cognitive and physical training: the role of training dosage and severity of neurocognitive disorder. Frontiers in Aging Neuroscience, 2015, 7, 152.	3.4	138
244	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	2.4	36
245	A novel biomarker of amnestic MCI based on dynamic cross-frequency coupling patterns during cognitive brain responses. Frontiers in Neuroscience, 2015, 9, 350.	2.8	87
246	Novel Virtual User Models of Mild Cognitive Impairment for Simulating Dementia. Computational and Mathematical Methods in Medicine, 2015, 2015, 1-15.	1.3	3
247	Circulating Proteomic Signatures of Chronological Age. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 809-816.	3.6	106
248	Age Effect in Human Brain Responses to Emotion Arousing Images: The EEG 3D-Vector Field Tomography Modeling Approach. IEEE Transactions on Autonomous Mental Development, 2015, 7, 223-235.	1.6	3
249	Phase-amplitude cross-frequency coupling in EEG-derived cortical time series upon an auditory perception task., 2015, 2015, 4150-3.		6
250	Sensor-based in-home monitoring of people with dementia using remote web technologies. , 2015, , .		12
251	Supporting Cognitive Skills of People Suffering from Dementia through a Sensor-Based System. , 2015, ,		4
252	Computerized Cognitive Testing for Older Adults. American Journal of Alzheimer's Disease and Other Dementias, 2015, 30, 13-28.	1.9	210

#	Article	IF	CITATIONS
253	Can a Virtual Reality Cognitive Training Application Fulfill a Dual Role? Using the Virtual Supermarket Cognitive Training Application as a Screening Tool for Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 44, 1333-1347.	2.6	123
254	Protective variant for hippocampal atrophy identified by whole exome sequencing. Annals of Neurology, 2015, 77, 547-552.	5.3	48
255	Linking Genetics of Brain Changes to Alzheimer's Disease: Sparse Whole Genome Association Scan of Regional MRI Volumes in the ADNI and AddNeuroMed Cohorts. Journal of Alzheimer's Disease, 2015, 45, 851-864.	2.6	10
256	Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease. Translational Psychiatry, 2015, 5, e494-e494.	4.8	105
257	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	7.6	284
258	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	3.1	30
259	On the Comparison of a Novel Serious Game and Electroencephalography Biomarkers for Early Dementia Screening. Advances in Experimental Medicine and Biology, 2015, 821, 63-77.	1.6	25
260	Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes. Translational Psychiatry, 2015, 5, e584-e584.	4.8	39
261	DNMT3A moderates cognitive decline in subjects with mild cognitive impairment: replicated evidence from two mild cognitive impairment cohorts. Epigenomics, 2015, 7, 533-537.	2.1	23
262	Automated Hippocampal Subfield Measures as Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease in Two Independent Cohorts. Brain Topography, 2015, 28, 746-759.	1.8	69
263	Helicobacter pylori infection, dementia and primary open-angle glaucoma: are they connected?. BMC Ophthalmology, 2015, 15, 24.	1.4	29
264	Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimer's Research and Therapy, 2015, 7, 17.	6.2	419
265	Simple UHPLC-DAD Method for the Direct Determination of Donepezil in Cerebrospinal Fluid. Journal of Liquid Chromatography and Related Technologies, 2015, 38, 1068-1072.	1.0	2
266	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
267	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
268	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	10.1	144
269	Brain source localization of MMN, P300 and N400: Aging and gender differences. Brain Research, 2015, 1603, 32-49.	2.2	52
270	FASTKD2 is associated with memory and hippocampal structure in older adults. Molecular Psychiatry, 2015, 20, 1197-1204.	7.9	33

#	Article	IF	CITATIONS
271	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
272	A Sensor-Based Framework to Support Clinicians in Dementia Assessment: The Results of a Pilot Study. Advances in Intelligent Systems and Computing, 2015, , 213-221.	0.6	8
273	A Review of Interventions with Assistive Technologies for Patients with Cognitive Impairment. Advances in Psychology, Mental Health, and Behavioral Studies, 2015, , 118-129.	0.1	3
274	An Ambient Intelligence System for the Monitoring, Empowerment, and Disease Evolution Prediction for Patients with Mild Cognitive Impairment. Advances in Psychology, Mental Health, and Behavioral Studies, 2015, , 225-239.	0.1	1
275	A Neglected Drama for Elders: Discrepancy Between Self-Perception and Objective Performance Regarding Financial Capacity in Patients With Cognitive Deficits. Psychological Thought, 2015, 8, 142-147.	0.3	18
276	New Technologies and Neuropsychological Evaluation of Older Adults. Advances in Psychology, Mental Health, and Behavioral Studies, 2015, , 1-17.	0.1	2
277	Cognitive Exercising for Patients with MCI Using Serious Games. Advances in Psychology, Mental Health, and Behavioral Studies, 2015, , 88-117.	0.1	O
278	Our experience with informative and communication technologies (ICT) in dementia. Hellenic Journal of Nuclear Medicine, 2015, 18 Suppl 1, 131-9.	0.3	7
279	Predicting Progression of Alzheimer's Disease Using Ordinal Regression. PLoS ONE, 2014, 9, e105542.	2.5	44
280	Electroencephalogram and Alzheimer's Disease: Clinical and Research Approaches. International Journal of Alzheimer's Disease, 2014, 2014, 1-10.	2.0	55
281	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. Frontiers in Aging Neuroscience, 2014, 6, 145.	3.4	29
282	Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness. Neurolmage: Clinical, 2014, 6, 115-125.	2.7	233
283	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. PLoS Medicine, 2014, 11, e1001713.	8.4	75
284	Advanced Bio-Feedback and Collaborative Techniques to Support Caregivers of Alzheimer Patients. , 2014, , .		4
285	P4-365: SERIOUS GAMING ENHANCES COGNITIVE FUNCTION IN MCI DUE TO ALZHEIMER'S DISEASE. , 2014, 10, P922-P922.		3
286	Influence of age, disease onset and <i>ApoE4</i> on visual medial temporal lobe atrophy cutâ€offs. Journal of Internal Medicine, 2014, 275, 317-330.	6.0	60
287	Dementia and Depression in Older Adults: A Southeast European Perspective: Summary of a Dementia Psychogeriatric Symposium held in Ohrid, Macedonia, 23 May 2013. Journal of Alzheimer's Disease, 2014, 41, 1251-1260.	2.6	2
288	Functional disorganization of small-world brain networks in mild Alzheimer's Disease and amnestic Mild Cognitive Impairment: an EEG study using Relative Wavelet Entropy (RWE). Frontiers in Aging Neuroscience, 2014, 6, 224.	3.4	87

#	Article	IF	Citations
289	Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 271-278.	3.1	256
290	Cognitive and physical training for the elderly: Evaluating outcome efficacy by means of neurophysiological synchronization. International Journal of Psychophysiology, 2014, 93, 1-11.	1.0	45
291	Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2883.e3-2883.e10.	3.1	9
292	Clinical workout for the early detection of cognitive decline and dementia. European Journal of Clinical Nutrition, 2014, 68, 1186-1191.	2.9	12
293	Multisite longitudinal reliability of tract-based spatial statistics in diffusion tensor imaging of healthy elderly subjects. NeuroImage, 2014, 101, 390-403.	4.2	99
294	Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer's and Dementia, 2014, 10, 799.	0.8	180
295	Sexual Function in Normal Elders, MCI and Patients with Mild Dementia. Sexuality and Disability, 2014, 32, 205-219.	1.0	12
296	The cerebrospinal fluid "Alzheimer profile― Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.8	249
297	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's and Dementia, 2014, 10, 724-734.	0.8	182
298	Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood. Neurobiology of Aging, 2014, 35, 279-290.	3.1	56
299	Can a novel computerized cognitive screening test provide additional information for early detection of Alzheimer's disease?., 2014, 10, 790-798.		62
300	CERAD Neuropsychological Compound Scores are Accurate in Detecting Prodromal Alzheimer's Disease: A Prospective AddNeuroMed Study. Journal of Alzheimer's Disease, 2014, 39, 679-690.	2.6	35
301	Cognitive Brain Signal Processing: Healthy vs Alzheimer's Disease Patients. Lecture Notes in Computer Science, 2014, , 503-514.	1.3	4
302	Assessing Virtual Reality Environments as Cognitive Stimulation Method for Patients with MCI. Studies in Computational Intelligence, 2014, , 39-74.	0.9	44
303	NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease. BMJ Open, 2014, 4, e006364.	1.9	47
304	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
305	Depression and Anxiety Levels Increase Chronic Musculoskeletal Pain in Patients with Alzheimer's Disease. Current Alzheimer Research, 2014, 11, 574-579.	1.4	20
306	Prevalence of Mild Cognitive Impairment in Individuals Aged over 65 in a Rural Area in North Greece. Advances in Alzheimer's Disease, 2014, 03, 11-19.	0.9	9

#	Article	IF	CITATIONS
307	Comparing Data from a Computer Based Intervention Program for Patients with Alzheimer's Disease. Lecture Notes in Computer Science, 2014, , 258-266.	1.3	1
308	Legal capacity of the elderly in Greece. Hellenic Journal of Nuclear Medicine, 2014, 17 Suppl 1, 2-6.	0.3	4
309	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
310	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. Neurobiology of Aging, 2013, 34, 2003-2013.	3.1	86
311	Could language deficits really differentiate Mild Cognitive Impairment (MCI) from mild Alzheimer's disease?. Archives of Gerontology and Geriatrics, 2013, 57, 263-270.	3.0	44
312	Candidate Blood Proteome Markers of Alzheimer's Disease Onset and Progression: A Systematic Review and Replication Study. Journal of Alzheimer's Disease, 2013, 38, 515-531.	2.6	160
313	Improved detection of amnestic MCI by means of discriminative vector quantization of single-trial cognitive ERP responses. Journal of Neuroscience Methods, 2013, 212, 344-354.	2.5	14
314	Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI. Neurology, 2013, 80, 1124-1132.	1.1	110
315	Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. Psychiatry Research - Neuroimaging, 2013, 212, 89-98.	1.8	98
316	The deletion variant of $\hat{l}\pm 2b$ -adrenergic receptor is associated with decreased risk in Alzheimer's disease and mild cognitive impairment. Journal of the Neurological Sciences, 2013, 328, 19-23.	0.6	12
317	Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. Molecular Psychiatry, 2013, 18, 781-787.	7.9	81
318	An MRIâ€based index to measure the severity of Alzheimer's diseaseâ€like structural pattern in subjects with mild cognitive impairment. Journal of Internal Medicine, 2013, 273, 396-409.	6.0	53
319	Identification of functional variants from whole-exome sequencing, combined with neuroimaging genetics. Molecular Psychiatry, 2013, 18, 739-739.	7.9	8
320	The Association Between APOE $\hat{l}\mu 4$ and Alzheimer-type Dementia Among Memory Clinic Patients is Confined to those with a Higher Education. The DESCRIPA Study. Journal of Alzheimer's Disease, 2013, 35, 241-246.	2.6	7
321	The Role of ABCA1 Gene Sequence Variants on Risk of Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 897-906.	2.6	45
322	Single-Domain Amnestic Mild Cognitive Impairment Identified by Cluster Analysis Predicts Alzheimer's Disease in the European Prospective DESCRIPA Study. Dementia and Geriatric Cognitive Disorders, 2013, 36, 1-19.	1.5	41
323	Classification and prediction of clinical diagnosis of Alzheimer's disease based on <scp>MRI</scp> and plasma measures of αâ€Ĵ³â€tocotrienols and γâ€tocopherol. Journal of Internal Medicine, 2013, 273, 602-621.	6.0	67
324	A Blood Gene Expression Marker of Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 737-753.	2.6	91

#	Article	IF	Citations
325	Entorhinal Cortex Thickness Predicts Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 755-766.	2.6	105
326	Classification Models for Alzheimer's Disease Detection. Communications in Computer and Information Science, 2013, , 193-202.	0.5	9
327	Inflammatory Proteins in Plasma Are Associated with Severity of Alzheimer's Disease. PLoS ONE, 2013, 8, e64971.	2.5	122
328	Ecological Validity of Virtual Reality Daily Living Activities Screening for Early Dementia: Longitudinal Study. JMIR Serious Games, 2013, 1, e1.	3.1	129
329	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. Neurology, 2012, 79, 1809-1816.	1.1	129
330	What are the symbols of Alzheimer? A permutation entropy based symbolic analysis for the detection of early changes of the electroencephalographic complexity due to mild Alzheimer., 2012,,.		0
331	Progression of Alzheimer Disease in Europe: Data from the European ICTUS Study. Current Alzheimer Research, 2012, 9, 902-912.	1.4	42
332	Mitochondrial Dysfunction and Immune Activation are Detectable in Early Alzheimer's Disease Blood. Journal of Alzheimer's Disease, 2012, 30, 685-710.	2.6	141
333	The Role of Variation at AβPP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 377-387.	2.6	53
334	Frontotemporal atrophy associated with paranoid delusions in women with Alzheimer's disease. International Psychogeriatrics, 2012, 24, 99-107.	1.0	36
335	Clinical Efficacy of Aniracetam, Either as Monotherapy or Combined with Cholinesterase Inhibitors, in Patients with Cognitive Impairment: A Comparative Open Study*. CNS Neuroscience and Therapeutics, 2012, 18, 302-312.	3.9	16
336	Alzheimer's disease and age-related macular degeneration have different genetic models for complement gene variation. Neurobiology of Aging, 2012, 33, 1843.e9-1843.e17.	3.1	24
337	The association between white matter hyperintensities and executive decline in mild cognitive impairment is network dependent. Neurobiology of Aging, 2012, 33, 201.e1-201.e8.	3.1	48
338	Tocopherols and tocotrienols plasma levels are associated with cognitive impairment. Neurobiology of Aging, 2012, 33, 2282-2290.	3.1	134
339	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiology of Aging, 2012, 33, 2272-2281.	3.1	75
340	Alzheimer's disease biomarker discovery using in silico literature mining and clinical validation. Journal of Translational Medicine, 2012, 10, 217.	4.4	26
341	Ondasetron versus haloperidol for the treatment of postcardiotomy delirium: a prospective, randomized, double-blinded study. Journal of Cardiothoracic Surgery, 2012, 7, 25.	1,1	40
342	Education increases reserve against Alzheimer's diseaseâ€"evidence from structural MRI analysis. Neuroradiology, 2012, 54, 929-938.	2.2	148

#	Article	IF	Citations
343	Plasma Based Markers of [11C] PiB-PET Brain Amyloid Burden. PLoS ONE, 2012, 7, e44260.	2.5	89
344	Helicobacter pylori infection and primary open-angle glaucoma: is there a connection?. Clinical Ophthalmology, 2012, 6, 45.	1.8	10
345	Identification of <i>cis-</i> regulatory variation influencing protein abundance levels in human plasma. Human Molecular Genetics, 2012, 21, 3719-3726.	2.9	94
346	A Mahalanobis Distance Based Approach towards the Reliable Detection of Geriatric Depression Symptoms Co-existing with Cognitive Decline. International Federation for Information Processing, 2012, , 16-25.	0.4	0
347	On the comparison of VR-responses, as performance measures in prospective memory, with auditory P300 responses in MCI detection. Studies in Health Technology and Informatics, 2012, 181, 156-61.	0.3	5
348	A Web services-based exergaming platform for senior citizens: The long lasting memories project approach to e-health care., 2011, 2011, 2505-9.		22
349	Evaluating affective usability experiences of an exergaming platform for seniors., 2011,,.		20
350	CERAD Neuropsychological Battery Total Score in Multinational Mild Cognitive Impairment and Control Populations: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2011, 22, 1089-1097.	2.6	40
351	Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neurolmage, 2011, 56, 212-219.	4.2	190
352	AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. NeuroImage, 2011, 58, 818-828.	4.2	121
353	Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neurolmage, 2011, 54, 1178-1187.	4.2	128
354	Cognitive event-related potentials: Longitudinal changes in mild cognitive impairment. Clinical Neurophysiology, 2011, 122, 1322-1326.	1.5	80
355	A Multiple Indicators Multiple Causes (MIMIC) model of Behavioural and Psychological Symptoms in Dementia (BPSD). Neurobiology of Aging, 2011, 32, 434-442.	3.1	64
356	Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groupsâ€"The AddNeuroMed study. Neurobiology of Aging, 2011, 32, 1198-1206.	3.1	69
357	Life events and dementia: What is the nature of their relationship?. Psychiatry Research, 2011, 190, 156-158.	3.3	14
358	Alzheimer's disease and primary open-angle glaucoma: is there a connection. Clinical Ophthalmology, 2011, 5, 887.	1.8	28
359	Combinatorial Markers of Mild Cognitive Impairment Conversion to Alzheimer's Disease - Cytokines and MRI Measures Together Predict Disease Progression. Journal of Alzheimer's Disease, 2011, 26, 395-405.	2.6	47
360	Sensitivity and Specificity of Medial Temporal Lobe Visual Ratings and Multivariate Regional MRI Classification in Alzheimer's Disease. PLoS ONE, 2011, 6, e22506.	2.5	103

#	Article	IF	Citations
361	Plasma Biomarkers of Brain Atrophy in Alzheimer's Disease. PLoS ONE, 2011, 6, e28527.	2.5	106
362	Do Instrumental Activities of Daily Living Predict Dementia at 1―and 2‥ear Followâ€Up? Findings from the Development of Screening Guidelines and Diagnostic Criteria for Predementia <scp>A</scp> lzheimer's Disease Study. Journal of the American Geriatrics Society, 2011, 59, 2273-2281.	2.6	59
363	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
364	Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Molecular Psychiatry, 2011, 16, 1130-1138.	7.9	133
365	Detection of elevated antibodies against SR protein kinase 1 in the serum of Alzheimer's disease patients. Journal of Neuroimmunology, 2011, 238, 67-72.	2.3	8
366	Effectiveness of Nonpharmacological Approaches in Patients with Mild Cognitive Impairment. Neurodegenerative Diseases, 2011, 8, 138-145.	1.4	77
367	The Complex Nature of Inappropriate Sexual Behaviors in Patients with Dementia: Can We Put it into a Frame?. Sexuality and Disability, 2011, 29, 143-156.	1.0	29
368	SPECT imaging evaluation in movement disorders: far beyond visual assessment. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 764-773.	6.4	77
369	The AddNeuroMed framework for multiâ€entre MRI assessment of Alzheimer's disease : experience from the first 24 months. International Journal of Geriatric Psychiatry, 2011, 26, 75-82.	2.7	127
370	Apathy and cortical atrophy in Alzheimer's disease. International Journal of Geriatric Psychiatry, 2011, 26, 741-748.	2.7	84
371	Epigenetic Mechanisms in Alzheimer's Disease. Current Medicinal Chemistry, 2011, 18, 1751-1756.	2.4	25
372	RHEA,* a Nonpharmacological Cognitive Training Intervention in Patients With Mild Cognitive Impairment. Topics in Geriatric Rehabilitation, 2011, 27, 289-300.	0.4	24
373	Regional Differences in Effects of <i>APOE</i> ε4 on Cognitive Impairment in Non-Demented Subjects. Dementia and Geriatric Cognitive Disorders, 2011, 32, 135-142.	1.5	18
374	Deep Sequencing of the Nicastrin Gene in Pooled DNA, the Identification of Genetic Variants That Affect Risk of Alzheimer's Disease. PLoS ONE, 2011, 6, e17298.	2.5	21
375	Depression, extrapyramidal symptoms, dementia and an unexpected outcome: a case report. Cases Journal, 2010, 3, 47.	0.4	4
376	Consensus statement on dementia education and training in Europe. Journal of Nutrition, Health and Aging, 2010, 14, 131-135.	3.3	31
377	Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2010, 9, 969-977.	10.2	377
378	Turning principles into practice in Alzheimer's disease. International Journal of Clinical Practice, 2010, 64, 1198-1209.	1.7	5

#	Article	IF	CITATIONS
379	Effect of APOE $\hat{l}\mu 4$ Allele on Cortical Thicknesses and Volumes: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2010, 21, 947-966.	2.6	82
380	APOE & Thicknesses and Volumes. Dementia and Geriatric Cognitive Disorders, 2010, 30, 229-237.	1.5	40
381	Combination of P300 and CSF & amp; #946; -Amyloid (1-42) Assays May Provide a Potential Tool in the Early Diagnosis of Alzheimers Disease. Current Alzheimer Research, 2010, 7, 295-299.	1.4	26
382	Association of Plasma Clusterin Concentration With Severity, Pathology, and Progression in Alzheimer Disease. Archives of General Psychiatry, 2010, 67, 739.	12.3	353
383	Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2010, 31, 1375-1385.	3.1	104
384	Severely stressful events and dementia: A study of an elderly Greek demented population. Psychiatry Research, 2010, 176, 51-54.	3.3	42
385	Drug Profile: Transdermal Rivastigmine Patch in the Treatment of Alzheimer Disease. CNS Neuroscience and Therapeutics, 2010, 16, 246-253.	3.9	25
386	Cerebrospinal Fluid Proteins in the Diagnosis of Alzheimers Disease. Recent Patents on CNS Drug Discovery, 2010, 5, 172-178.	0.9	5
387	Cluster Analysis and Decision Trees of MR Imaging in Patients Suffering Alzheimer's. Advances in Intelligent and Soft Computing, 2010, , 477-484.	0.2	1
388	Progression of Mild Cognitive Impairment to Alzheimer's Disease: Improved Diagnostic Value of the Combined Use of N200 Latency and β-Amyloid(1–42) Levels. Dementia and Geriatric Cognitive Disorders, 2009, 28, 30-35.	1.5	28
389	Attitudes and Perceptions Regarding Alzheimer's Disease in Greece. American Journal of Alzheimer's Disease and Other Dementias, 2009, 24, 21-26.	1.9	29
390	Severe Psychological Stress in Elderly Individuals: A Proposed Model of Neurodegeneration and Its Implications. American Journal of Alzheimer's Disease and Other Dementias, 2009, 24, 85-94.	1.9	20
391	Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an international survey. Current Medical Research and Opinion, 2009, 25, 3059-3068.	1.9	24
392	Increased Cerebrospinal Fluid Helicobacter Pylori Antibody in Alzheimer's Disease. International Journal of Neuroscience, 2009, 119, 765-777.	1.6	96
393	Prediction of Conversion from Mild Cognitive Impairment to Alzheimer ' s Disease by CSF Cytochrome c Levels and N200 Latency. Current Alzheimer Research, 2009, 6, 279-284.	1.4	20
394	Rivastigmine for Alzheimer's disease., 2009,, CD001191.		104
395	Eradication of Helicobacter pylori may be beneficial in the management of Alzheimer's disease. Journal of Neurology, 2009, 256, 758-767.	3.6	150
396	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	21.4	2,697

#	Article	IF	CITATIONS
397	MRI Measures of Alzheimer's Disease and the AddNeuroMed Study. Annals of the New York Academy of Sciences, 2009, 1180, 47-55.	3.8	121
398	AddNeuroMedâ€"The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 36-46.	3.8	193
399	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	7.4	1,009
400	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurology, The, 2009, 8, 619-627.	10.2	542
401	Male patient with mild cognitive impairment and extremely high P300 and Slow-wave latencies: a case report. Cases Journal, 2009, 2, 6157.	0.4	O
402	Alzheimer's dementia and post-traumatic stress disorder differences and similarities in neuroimaging. Hellenic Journal of Nuclear Medicine, 2009, 12, 41-6.	0.3	10
403	Ascertaining lateâ€life depressive symptoms in Europe: an evaluation of the survey version of the EUROâ€D scale in 10 nations. The SHARE project. International Journal of Methods in Psychiatric Research, 2008, 17, 12-29.	2.1	125
404	Are Genetic Components Related to Cognitive Decline After Coronary Artery Surgery? Genetics and Brain Function after Bypass Heart Surgery. Journal of Cardiac Surgery, 2008, 23, 280-281.	0.7	2
405	Usefulness of event-related potentials in the assessment of mild cognitive impairment. BMC Neuroscience, 2008, 9, 107.	1.9	98
406	Importance of circadian rhythmicity in the cholinergic treatment of Alzheimer's disease: focus on galantamine. Current Medical Research and Opinion, 2008, 24, 3357-3367.	1.9	37
407	Consistency of Neuropsychiatric Syndromes across Dementias: Results from the European Alzheimer Disease Consortium. Dementia and Geriatric Cognitive Disorders, 2008, 25, 1-8.	1.5	167
408	Patient and Caregiver Perspectives of Quality of Life in Dementia. Dementia and Geriatric Cognitive Disorders, 2008, 26, 138-146.	1.5	151
409	Development of Screening Guidelines and Clinical Criteria for Predementia Alzheimer's Disease. Neuroepidemiology, 2008, 30, 254-265.	2.3	86
410	Practice of Competence Assessment in Dementia: Greece., 2008, , 121-124.		0
411	Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy. Current Medical Research and Opinion, 2007, 23, 3153-3165.	1.9	4
412	Prevalence of depressive symptoms and syndromes in later life in ten European countries. British Journal of Psychiatry, 2007, 191, 393-401.	2.8	215
413	The Role of Apolipoprotein E in Cognitive Decline and Delirium after Bypass Heart Operations. American Journal of Alzheimer's Disease and Other Dementias, 2007, 22, 223-228.	1.9	55
414	Neuropsychiatric Syndromes in Dementia. Dementia and Geriatric Cognitive Disorders, 2007, 24, 457-463.	1.5	305

#	Article	IF	Citations
415	Identification of the Genetic Basis for Complex Disorders by Use of Pooling-Based Genomewide Single-Nucleotide–Polymorphism Association Studies. American Journal of Human Genetics, 2007, 80, 126-139.	6.2	139
416	Association between <i>Helicobacter pylori</i> infection and mild cognitive impairment. European Journal of Neurology, 2007, 14, 976-982.	3.3	74
417	The role of SOAT-1 polymorphisms in cognitive decline and delirium after bypass heart surgery. Clinical Research in Cardiology, 2007, 96, 600-603.	3.3	12
418	Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics, 2007, 8, 179-188.	1.4	47
419	Functional cognitive assessment scale (FUCAS): a new scale to assess executive cognitive function in daily life activities in patients with dementia and mild cognitive impairment. Human Psychopharmacology, 2006, 21, 305-311.	1.5	62
420	Ethnicity-dependent genetic association of ABCA2 with sporadic Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 534-536.	1.7	53
421	No association of a non-synonymousPLAU polymorphism with Alzheimer's disease and disease-related traits. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 132B, 21-23.	1.7	16
422	Cholesterol 25-Hydroxylase on Chromosome 10q Is a Susceptibility Gene for Sporadic Alzheimer's Disease. Neurodegenerative Diseases, 2005, 2, 233-241.	1.4	55
423	Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. European Psychiatry, 2005, 20, 490-496.	0.2	177
424	Focus on Alzheimer's Disease and Related Disorders. Journal of Clinical Psychiatry, 2005, 66, 940-947.	2.2	97
425	Serum estradiol, progesterone, testosterone, FSH and LH levels in postmenopausal women with Alzheimer's dementia. Hellenic Journal of Nuclear Medicine, 2005, 8, 39-42.	0.3	25
426	A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. Journal of Clinical Psychiatry, 2005, 66, 940-7.	2.2	47
427	Role for glyoxalase I in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 7687-7692.	7.1	150
428	Folic acid and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2003, 18, 187-188.	2.7	11
429	Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. Molecular Psychiatry, 2003, 8, 635-638.	7.9	59
430	Clock drawing test in institutionalized patients with schizophrenia compared with Alzheimer's disease patients. Schizophrenia Research, 2003, 59, 173-179.	2.0	19
431	ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiology of Aging, 2003, 24, 421-426.	3.1	148
432	Glucocorticoid-related genetic susceptibility for Alzheimer's disease. Human Molecular Genetics, 2003, 13, 47-52.	2.9	103

#	Article	IF	CITATIONS
433	Increased Brain Î ² -Amyloid Load, Phosphorylated Tau, and Risk of Alzheimer Disease Associated With an Intronic CYP46 Polymorphism. Archives of Neurology, 2003, 60, 29.	4.5	210
434	Greek validation of the Seven-Minute Screening Battery for Alzheimer's disease in the elderly. American Journal of Alzheimer's Disease and Other Dementias, 2002, 17, 139-148.	1.9	14
435	Wechsler Memory Scale, Rivermead Behavioral Memory Test, and Everyday Memory Questionnaire in Healthy Adults and Alzheimer Patients. European Journal of Psychological Assessment, 2002, 18, 63-77.	3.0	58
436	Evaluation of tiapride in agitated elderly outpatients: an open study. Human Psychopharmacology, 2001, 16, 417-422.	1.5	3
437	Efficacy of Acetylcholinesterase Inhibitors versus Nootropics in Alzheimer's Disease: A Retrospective, Longitudinal Study. Journal of International Medical Research, 2001, 29, 28-36.	1.0	18
438	Investigation of 'borderline' dementia, particularly of Alzheimer's type, compared with non-demented patients with similar neuropsychological profiles. International Journal of Psychiatry in Clinical Practice, 2001, 5, 55-61.	2.4	3
439	Hindi Mental State Examination (HMSE) as a screening test for illiterate demented patients. International Journal of Geriatric Psychiatry, 2000, 15, 662-664.	2.7	34
440	The Cambridge Cognitive Examination (CAMCOG): A validation study in outpatients suffering from dementia and non-demented elderly subjects (including Age Associated Cognitive Decline patients) in Greece. American Journal of Alzheimer's Disease and Other Dementias, 2000, 15, 269-276.	1.9	14
441	Monotherapy with Lamotrigine in patients with Alzheimer's disease and seizures., 2000, 15, 74-79.		5
442	Changes in pupil reaction to light in Alzheimer's disease patients: a preliminary report. International Journal of Psychophysiology, 2000, 37, 111-120.	1.0	91
443	Validation of the Epidemiological Dementia Index in Geriatric Outpatients. International Psychogeriatrics, 2000, 12, 195-208.	1.0	15
444	Rivastigmine for Alzheimer's disease. , 2000, , CD001191.		119
445	Target symptoms for fluvoxamine in old age depression. International Journal of Psychiatry in Clinical Practice, 2000, 4, 127-134.	2.4	3
446	Prevalence and incidence of Alzheimers disease and other dementing disorders in Pylea, Greece. , 1999, 14, 138-148.		27
447	Changes in pupil reaction to light in melancholic patients. International Journal of Psychophysiology, 1999, 31, 121-128.	1.0	39
448	Absence of Oligoclonal IgG Bands and Anti-Achr Antibodies in the Cerebrospinal Fluid of Patients with Myasthenia Gravis. International Journal of Immunopathology and Pharmacology, 1998, 11, 87-90.	2.1	1
449	Epidemiological Dementia Index: A Screening Instrument for Alzheimer's Disease and Other Types of Dementia Suitable for Use in Populations with Low Education Level. Dementia and Geriatric Cognitive Disorders, 1998, 9, 329-338.	1.5	24
450	Alzheimer's Disease Assessment Scale: The Validation of the Scale in Greece in Elderly Demented Patients and Normal Subjects. Dementia and Geriatric Cognitive Disorders, 1997, 8, 273-280.	1.5	35

#	Article	lF	CITATIONS
451	Risk Factors for Clinically Diagnosed Alzheimer's Disease: A Case-Control Study of a Greek Population. International Psychogeriatrics, 1997, 9, 327-341.	1.0	59
452	Hypoxic pretreatment protects against neuronal damage of the rat hippocampus induced by severe hypoxia. Brain Research, 1996, 714, 215-225.	2.2	38
453	Correlation of Dementia, Neuropsychological and MRI Findings in Multiple Sclerosis. Dementia and Geriatric Cognitive Disorders, 1994, 5, 48-52.	1.5	22
454	Cytogenetic damage by melphalan and hyperthermia in patients with an initial epileptic attack. Mutation Research - Genetic Toxicology Testing and Biomonitoring of Environmental Or Occupational Exposure, 1992, 280, 143-148.	1.2	3
455	Phenytoin plasma levels after intraoperative administration, for the prevention of post-craniotomy seizures. Acta Neurochirurgica, 1987, 84, 36-38.	1.7	13
456	Cognitive Exercising for Patients With MCI Using Serious Games. , 0, , 1313-1342.		1
457	New Technologies and Neuropsychological Evaluation of Older Adults. , 0, , 1762-1779.		2
458	A Review of Interventions with Assistive Technologies for Patients with Cognitive Impairment. , 0, , 1269-1281.		0